Array-based gene expression, CGH and tissue data defines a 12q24 gain in neuroblastic tumors with prognostic implication

TamPub

Kuvailutiedot

dc.contributor.author Wolf, Maija -
dc.contributor.author Korja, Miikka -
dc.contributor.author Karhu, Ritva -
dc.contributor.author Edgren, Henrik -
dc.contributor.author Kilpinen, Sami -
dc.contributor.author Ojala, Kalle -
dc.contributor.author Mousses, Spyro -
dc.contributor.author Kallioniemi, Anne -
dc.contributor.author Haapasalo, Hannu -
dc.date.accessioned 2012-06-17T20:16:30Z
dc.date.available 2012-06-12 22:05:58 -
dc.date.available 2012-06-17T20:16:30Z
dc.date.issued 2010 -
dc.identifier.issn 1471-2407 -
dc.identifier.uri http://tampub.uta.fi/handle/10024/66262
dc.description BioMed Central Open access -
dc.description.abstract Background Neuroblastoma has successfully served as a model system for the identification of neuroectoderm-derived oncogenes. However, in spite of various efforts, only a few clinically useful prognostic markers have been found. Here, we present a framework, which integrates DNA, RNA and tissue data to identify and prioritize genetic events that represent clinically relevant new therapeutic targets and prognostic biomarkers for neuroblastoma. Methods A single-gene resolution aCGH profiling was integrated with microarray-based gene expression profiling data to distinguish genetic copy number alterations that were strongly associated with transcriptional changes in two neuroblastoma cell lines. FISH analysis using a hotspot tumor tissue microarray of 37 paraffin-embedded neuroblastoma samples and in silico data mining for gene expression information obtained from previously published studies including up to 445 healthy nervous system samples and 123 neuroblastoma samples were used to evaluate the clinical significance and transcriptional consequences of the detected alterations and to identify subsequently activated gene(s). Results In addition to the anticipated high-level amplification and subsequent overexpression of MYCN, MEIS1, CDK4 and MDM2 oncogenes, the aCGH analysis revealed numerous other genetic alterations, including microamplifications at 2p and 12q24.11. Most interestingly, we identified and investigated the clinical relevance of a previously poorly characterized amplicon at 12q24.31. FISH analysis showed low-level gain of 12q24.31 in 14 of 33 (42%) neuroblastomas. Patients with the low-level gain had an intermediate prognosis in comparison to patients with MYCN amplification (poor prognosis) and to those with no MYCN amplification or 12q24.31 gain (good prognosis) (P = 0.001). Using the in silico data mining approach, we identified elevated expression of five genes located at the 12q24.31 amplicon in neuroblastoma (DIABLO, ZCCHC8, RSRC2, KNTC1 and MPHOSPH9). Among these, DIABLO showed the strongest activation suggesting a putative role in neuroblastoma progression. Conclusions The presented systematic and rapid framework, which integrates aCGH, gene expression and tissue data to obtain novel targets and biomarkers for cancer, identified a low-level gain of the 12q24.31 as a potential new biomarker for neuroblastoma progression. Furthermore, results of in silico data mining suggest a new neuroblastoma target gene, DIABLO, within this region, whose functional and therapeutic role remains to be elucidated in follow-up studies. -
dc.language.iso en -
dc.title Array-based gene expression, CGH and tissue data defines a 12q24 gain in neuroblastic tumors with prognostic implication -
dc.type fi=Artikkeli aikakauslehdessä | en=Journal article| -
dc.identifier.urn urn:nbn:uta-3-527 -
dc.identifier.doi 10.1186/1471-2407-10-181 -
dc.type.version fi=Kustantajan versio | en=Publisher's version| -
dc.subject.okm fi=Lääketieteen bioteknologia | en=Medical biotechnology| -
dc.journal.title BMC Cancer -
dc.journal.volume 10 -
dc.journal.number 181 -
dc.journal.volumepagerange 1-13 -
dc.oldstats 73 -

Viite kuuluu kokoelmiin:

Kuvailutiedot